The Future of XMT-1536 in Ovarian Cancer and NSCLC

September 14, 2016

Don Bergstrom, MD, PhD, chief medical officer, Mersana Therapeutics, discusses the future of XMT-1536 in the treatment of ovarian cancer and non-small cell lung cancer (NSCLC).